TuHURA Biosciences, Inc.(HURA) - 2025 Q4 - Annual Results

FORM 8-K Filing Details This section outlines the administrative and securities information pertinent to the Form 8-K filing Registrant and Filing Information This section provides administrative details of the Form 8-K filing, including registrant identity and event date - The registrant is TUHURA BIOSCIENCES, INC., incorporated in Nevada, with its principal executive offices in Tampa, Florida[2] - The date of the earliest event reported in this filing is August 14, 2025[2] Securities Information This section details the registrant's registered securities and its status concerning emerging growth company provisions Registered Securities | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | :------------------ | :---------------- | :---------------------------------------- | | Common Stock, $0.001 par value per share | HURA | The Nasdaq Capital Market | - The registrant has indicated that it is not an emerging growth company[6] Current Report Items This section details the specific items reported in the Form 8-K, including financial results and accompanying exhibits Item 2.02 Results of Operations and Financial Condition This item reports TuHURA Biosciences, Inc. issued a press release detailing financial results for Q2 2025 and a corporate update - On August 14, 2025, TuHURA Biosciences, Inc. issued a press release reporting financial results for the three months ended June 30, 2025, and providing a corporate update[7] - The press release (Exhibit 99.1) is attached to this Current Report and incorporated by reference, but the information is furnished and not deemed 'filed' for most purposes[7] Item 9.01 Financial Statements and Exhibits This item lists the exhibits accompanying the Form 8-K filing, which include the press release with financial results and the interactive data file List of Exhibits | Exhibit No. | Document | | :------------ | :---------------------------------------------------- | | 99.1 | Press Release, dated August 14, 2025 | | 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | SIGNATURES This section provides the formal signatures, confirming the authorization and submission of the report Report Signatures This section formally concludes the Form 8-K filing with the required signatures, confirming the registrant's authorization - The report was signed on August 14, 2025, by Dan Dearborn, Chief Financial Officer of TUHURA BIOSCIENCES, INC.[13]